SCHEMBL3471881

SCHEMBL3471881

O=C(O)Nc1nc2ccc(C(=O)c3ccccc3C(=O)Nc3cccc(F)c3)cc2[nH]1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAF1 P04049 5/20 0.59
▸ BRAF P15056 5/20 0.59
▸ MTOR P42345 1/20 0.55
▸ NPC1 O15118 4/20 0.51
▸ RAB9A P51151 3/20 0.51
▸ CYP2C9 P11712 3/20 0.51
▸ MAPT P10636 3/20 0.51
▸ CYP2C19 P33261 2/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ HTT P42858 3/20 0.49
▸ ALDH1A1 P00352 3/20 0.49
▸ ABL1 P00519 3/20 0.49
▸ LMNA P02545 3/20 0.49
▸ KDR P35968 2/20 0.49
▸ CYP1A2 P05177 2/20 0.49
▸ ABCC4 O15439 1/20 0.49
▸ USP2 O75604 1/20 0.49
▸ HIF1A Q16665 1/20 0.49
▸ KDM4E B2RXH2 3/20 0.48
▸ HPGD P15428 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3853135 0.90 RAF1 (0.72) RAF1BRAFMTORNPC1CYP2C9
SCHEMBL2357955 0.89 RAF1 (0.63) RAF1BRAFNPC1RAB9ACYP2C9
SCHEMBL2356348 0.88 RAF1 (0.59) RAF1BRAFNPC1RAB9ACYP2C9
SCHEMBL3473662 0.88 RAF1 (0.59) RAF1BRAFRAB9ACYP2C9MAPT
SCHEMBL3475822 0.88 RAF1 (0.59) RAF1BRAFNPC1RAB9ACYP2C9
SCHEMBL1792255 0.88 RAF1 (0.57) RAF1BRAFMAPTKDRRXFP1
SCHEMBL2297881 0.87 RAF1 (0.58) RAF1BRAFNPC1RAB9ACYP2C9
SCHEMBL3474868 0.87 RAF1 (0.60) RAF1BRAFNPC1RAB9ACYP2C9
SCHEMBL1791971 0.86 RAF1 (0.64) RAF1BRAFNPC1RAB9ACYP2C9
SCHEMBL2299280 0.86 RAF1 (0.57) RAF1BRAFNPC1RAB9ACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP claimed
US-7846959-B2 Raf modulators and methods of use EXELIXIS, INC. (US) 2010-12-07 — — US claimed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP disclosed
EP-2139483-B9 COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER EXELIXIS INC (US) 2014-05-21 — — EP disclosed
EP-2139483-B1 COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER EXELIXIS INC (US) 2013-09-18 — — EP disclosed
Send feedback